[HTML][HTML] Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside

SB Gibson, MB Bromberg - Seminars in neurology, 2012 - thieme-connect.com
Amyotrophic lateral sclerosis (ALS) is an unrelenting progressive neurodegenerative
disease causing progressive weakness, ultimately leading to death. Despite aggressive …

Therapeutic neuroprotective agents for amyotrophic lateral sclerosis

RS Pandya, H Zhu, W Li, R Bowser… - Cellular and molecular …, 2013 - Springer
Amyotrophic lateral sclerosis (ALS) is a fatal chronic neurodegenerative disease whose
hallmark is proteinaceous, ubiquitinated, cytoplasmic inclusions in motor neurons and …

Prospects for the pharmacotherapy of amyotrophic lateral sclerosis: old strategies and new paradigms for the third millennium

BW Festoff, Z Suo, BA Citron - CNS drugs, 2003 - Springer
Biomedical researchers interested in amyotrophic lateral sclerosis (ALS) must invoke newly
developing technologies if we are to discover pharmaceutical treatments that will help a …

Amyotrophic lateral sclerosis: mechanisms and therapeutic strategies

L Van Den Bosch - Disease-Modifying Targets in Neurodegenerative …, 2017 - Elsevier
Selective death of upper and lower motor neurons in the motor cortex, brainstem, and spinal
cord is the hallmark of amyotrophic lateral sclerosis (ALS). ALS is a neurodegenerative …

Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis

J Costa, C Gomes… - CNS & Neurological …, 2010 - ingentaconnect.com
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease of the motor
system. The diagnosis is clinical, but additional investigations such as electromyography …

Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis

JA Morren, N Galvez-Jimenez - Expert Opinion on Investigational …, 2012 - Taylor & Francis
Introduction: Amyotrophic lateral sclerosis (ALS) is a devastating illness of unclear etiology
affecting motor neurons. It causes unremitting muscle paralysis, atrophy and death usually …

Emerging drugs for the treatment of amyotrophic lateral sclerosis: a focus on recent phase 2 trials

A Barp, F Gerardi, A Lizio, VA Sansone… - Expert Opinion on …, 2020 - Taylor & Francis
Introduction Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative
disease involving both upper and lower motor neurons and resulting in increasing disability …

The glutamate hypothesis in ALS: pathophysiology and drug development

H Blasco, S Mavel, P Corcia… - Current medicinal …, 2014 - ingentaconnect.com
Amyotrophic lateral sclerosis (ALS) is an age-related neurodegenerative disorder that is
believed to have complex genetic and environmental influences in the pathogenesis, but …

Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents

SA Johnson, T Fang, F De Marchi, D Neel… - Drugs, 2022 - Springer
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …

[HTML][HTML] Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials

PH Gordon - Aging and disease, 2013 - ncbi.nlm.nih.gov
Amyotrophic lateral sclerosis (ALS), first described by Jean-Martin Charcot in the 1870s, is
an age-related disorder that leads to degeneration of motor neurons. The disease begins …